This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Pubertal Blockade and Estradiol Effects on Cardiometabolic Health for Transitioning Youth

Sponsored by University of Colorado, Denver

About this trial

Last updated 2 years ago

Study ID

19-1226

Status

Recruiting

Type

Observational

Placebo

No

Accepting

18-75 Years
13 to 16 Years
All
All

Trial Timing

Ended a month ago

What is this trial about?

To evaluate the effect of estradiol with or without a prior gonadotropin releasing hormone analogue on insulin sensitivity and vascular function in transgender females compared to cisgender controls.

What are the Participation Requirements?

Inclusion Criteria (transgender females):

- Identify as a transgender female

- Age 13-16 years at the time of enrollment

- If on a gonadotropin releasing hormone analogue, > 6 months exposure

- Plan to start estradiol clinically in < 4 months

Inclusion Criteria (cisgender males and females):

- Males and females ages 13-16 years

Exclusion Criteria:

- Cognitive, psychiatric, or physical impairment resulting in inability to tolerate the
study procedures

- Antipsychotic medication use

- Type 1 or 2 diabetes (by medical history)

- Polycystic ovarian syndrome (PCOS for cisgender females)

- Hypertension (resting BP ≥ 140/90 mm/Hg)

- Weight> 400 lbs

- On oral progesterone medications (including oral progesterone or progestin, combined
oral contraceptives or etonogestrel implant)

- Pregnancy (for cisgender females)

Locations

Location

Status

Recruiting